Squamous cell carcinoma - Suragėjusių Ląstelių Karcinoma
☆ 2022 m. Stiftung Warentest iš Vokietijos rezultatai rodo, kad vartotojų pasitenkinimas ModelDerm buvo tik šiek tiek mažesnis nei mokamų nuotolinės medicinos konsultacijų.
Squamous cell carcinoma well differentiated ― Pastebima gretima aktininė keratozė.
References
Squamous cell carcinoma (SCC) yra antras pagal dažnumą odos vėžys Jungtinėse Valstijose po basal cell carcinoma. Paprastai jis prasideda nuo ikivėžinių pakitimų, vadinamų actinic keratosis , ir gali išplisti į kitas kūno dalis. Pagrindinė priežastis – saulės ultravioletinė (UV) spinduliuotė, kuri laikui bėgant kaupiasi. Gydymas paprastai apima chirurginį pašalinimą, ypač galvos ir kaklo SCC. Radiacinė terapija yra galimybė vyresnio amžiaus pacientams arba tiems, kuriems negalima atlikti operacijos. Imunosupresija padidina SCC riziką. Nors ir retai, SCC gali plisti, ypač pacientams, kurių imuninė sistema nusilpusi. Reguliarūs patikrinimai ir apsauga nuo saulės yra svarbūs tiems, kurie serga SCC.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) yra antras pagal dažnumą žmonių vėžys, ir jo skaičius didėja. Nors CSCC paprastai pasižymi gerybiniu klinikiniu elgesiu, jis gali plisti tiek lokaliai, tiek į kitas kūno dalis. Mokslininkai nustatė konkrečius būdus, susijusius su CSCC kūrimu, todėl atsirado naujų gydymo būdų. Didelis mutacijų skaičius ir padidėjusi rizika pacientams, kurių imunitetas slopinamas, paskatino imunoterapijos plėtrą. Šioje apžvalgoje nagrinėjamos genetinės CSCC šaknys ir naujausi gydymo būdai, skirti konkrečioms molekulėms ir imuninei sistemai.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Diagnostika ir gydymas
#Dermoscopy
#Skin biopsy